The Pharmaceutical world and those involved with the manufacture of sterile products are anxiously looking out for the publication of the final approved revision of ...

Annex 1 “Manufacture of Sterile Medicinal Products” was first published in 1971 and forms part of EudraLex Volume 4 [1], which interprets the basic principles of GMP...

The strategies used to create and maintain strong-pharmaceutical patent portfolios must evolve with developments in the pharmaceutical space. These developments incl...

The challenge of ensuring healthcare sustainability, the rise in more targeted treatments, and a shift in emphasis to preventative interventions, not to mention the ...

Companies must safeguard their mature portfolios while continuously innovating and developing new products. But in-house resources are stretched and often lack the b...

The process of developing a revolutionary medical device from the proof-of-concept stage to the marketing stage is expensive and complicated. The creation of a new p...

The application of high throughput screening techniques and computational chemistry has resulted in a marked shift in drug candidates with identified therapeutic pot...

Advances in combinatorial chemistry and high-throughput screening continue to introduce poorly water-soluble active ingredient (API) chemistries into pharmaceutical ...

Nearly all synthetic steps in industrial chemical manufacturing end with crystallisation. This is because it is almost always the most efficient method to purify and...

Technological advances in drug manufacturing equipment and process optimisation play a significant role in increasing the speed of the clinic of critical biologic dr...